Financial problems of governments and the consequent urge to set limits on health care growth have increased the importance of economic rationalization. A systematic review of the present body of knowledge might facilitate the need to set priorities in health care policies and research in an ageing society with growing numbers of the elderly and chronically ill. After explaining the purpose and methods of full economic evaluation, we review the literature on 3 major chronic diseases, diabetes mellitus (20 publications), rheumatoid arthritis (15) and chronic obstructive pulmonary disease (COPD) and asthma (8). This review serves 2 objectives: to review the existing literature and to assess its quality. The review reveals a lack of full economic evaluation in this sector of health care. The total number of references to the specified chronic diseases covers 5% of all economic literature and 44% of all references under Index Medicus' heading 'economies', while the burden of illness is substantial, resulting in high indirect costs to the patients themselves and to society. The dominant approach is cost-effectiveness analysis (71%), followed by cost-benefit analysis (20%). Cost-utility analysis is rare (9%), partly because it is still in the phase of development. However, this approach can deal better with the objectives of many interventions in chronic care, i.e. increasing the quality rather than the quantity of life. We make a plea for full economic evaluation of chronic care programmes and for the development of quality of life measures which cover the broad domain of well-being of the chronically ill.
wi th ageing populations and the strong relation between prevalences of chronic diseases and age, there will be increasing numbers of people with chronic diseases, of which many depend on the provision of health care. In this article, we adhere to the viewpoint that in ageing societies the burden of illness which comes with chronic diseases is a relevant starting point for establishing priorities for health care programmes and economic evaluation (besides the traditional focus on interventions), thus adopting the measurement iterative model of Tugwell et al. from quantifying the burden of illness, through aetiology to validating interventions and their evaluation. Others have addressed the demographic and epidemiological trends, which we need to discuss briefly in order to substantiate our viewpoint and to gain more insight into the effects of an ageing society. At first glance, there seems to be little information from the literature that could be used to support policy choices based on economic (other than, for instance, societal or ethical) considerations of the costs and outcomes of alternative health care programmes in the complex area of care for the chronically ill. Figures of the use of care resources are difficult to provide and there have been few attempts to analyse economically programmes particularly targeted at the elderly and chronically ill. Therefore, after explaining the purposes and methods of full economic evaluation, we review the literature on full economic evaluation of care for the chronically ill. This review serves 2 objectives: to review the existing literature and to assess its quality.
SELECTION OF EMPIRICAL FIELD: 3 CHRONIC DISEASES
Practical limitations made us carefully select 3 major chronic diseases, serving as a kind of case study for the total field of chronic diseases. We selected diabetes mellitus (DM), rheumatoid arthritis (RA), and chronic obstructive pulmonary disease (COPD) and asthma. These chronic diseases have been chosen for several reasons: a) in The Netherlands they rank among the top 10 diseases and causes of death in the general population 2 , b) they cause a severe burden of illness for both the individual patient and society and c) their prevalence rates are highly related to age (table I) , which is of great importance to an ageing society.
SOME RELEVANT TRENDS AND THEIR IMPACT ON THE CARE SECTOR
With variation between countries, the demographic trend is unmistakeably towards a larger population of the (very) old. In Western Europe, the number of elderly above 65 years is higher in Denmark, Belgium, Eastern Germany and the UK (almost 16%) than in The Netherlands (13%).-' A similar picture can be seen for the percentage of 85 years and over. Double-ageing, i.e. an increasing share of die very old widiin the population of elderly, is concentrated in females. Predictions on the future situation in die Dutch population show an increasing share of die elderly in die total population, to up to 24% by die year 2040. 4 Simple extrapolation for die year 2000, combining demographic trends widi age-specific care consumption rates have shown tiiat The Netherlands will experience a yearly increase in patients of approximately 2%. 5 ' 6 By the turn of die century, total expenditure will increase by 20-25% in real terms. The share of the elderly widiin die client populations of health care services, which in The Netherlands was on average already 40% in 1990, will rise further.'' Such extrapolations are unsatisfactory for a number of reasons. First, one may expect age-specific demands to shift over time. Subsequent cohorts do not just get older, but their health status also improves over time, due to changing healdi habits and attitudes and more effective prevention and curative programmes. This may lead to a concentration of illness in die last years of life, but it may also cause longer periods of illness, albeit at later stages in life. Many doubt whedier die age-specific prevalences of a number of important chronic diseases (table I) will change significantly in the coming years. Nevertheless, when age-specific prevalences remain more or less stable, die double-ageing of die population and the strong relation between prevalences and age, will inevitably result in increasing numbers of chronically ill. It is not only the prevalence but also the intensity of healdi care consumption which increases with age. Thus, die average cost per year per person is substantially higher in older dian in younger age groups (table 2) .' For women in the highest age brackets the figures are even 30% higher. Mental disorders are die most expensive disease category, accounting for 20% of all health care costs and 30% of all traceable diagnosis-related costs. For the elderly of 80 years and over the average cost related to dementia accounts for 18% of all costs. The costs related to dementia will double towards die year 2030. Also, die costs of some of tile chronic diseases which we focus on in diis article belong to the group of diseases widi die sharpest increases in costs during die decades to come. Setting the Anotiier departure from die simple extrapolation arises from the fact that technology in the area of service delivery for die elderly and chronically ill may also progress. There is considerable scope for the introduction of (new) technologies which may help people to stay independent and postpone die use of institutional care. 8 However, taking technological development in die 'cure' sector as an example, it is not self-evident that technological change will make die production of services less expensive because it is often aimed at increasing the effectiveness of interventions rather dian saving costs.
ECONOMIC APPRAISAL Relevance The trends we described above, result in a growing gap between the demand for services and die resources available from die public budget to finance these demands. One of die options to bridge diis gap is to increase the efficiency of public spending and healdi care policy, in which economic appraisal is playing an increasing role. Some countries, such as Australia and Canada, already use economic appraisal as an integrated part of their decisions on die reimbursement of new pharmaceutical products. In most developed 1,000 inhabitants), by gender countries major decisions on, for instance, die initiation of screening programmes are not taken without consideration of dieir cost-effectiveness profiles. These initiatives concentrate on the cure sector; policy decisions widiin die care sector seem to lack an economic foundation. Until now, die costs of most services have not been evaluated and die outcomes of most care provisions have not been measured. 9 There- Figure Different forms of economic appraisal fore, a review of die literature on economic analysis of care for the elderly and chronically ill may be useful.
Different methods
Only those studies which make a simultaneous comparison between alternative strategies and where bodi die costs and outcomes are being considered, are seen as full economic evaluations ( figure) . Drummond et al. 10 define full economic evaluation as "die comparative analysis of alternative courses of action in bodi dieir costs and consequences". This definition rules out odier forms of research, such as randomized clinical trials or efficacy evaluations (which assess only the outcomes of clinical strategies) and cost analysis and cost of illness studies (which exclude die outputs of programmes). These forms of partial economic evaluation often result in estimated cost per (treated) patient and can be useful if die effectiveness of alternative strategies has been well established or does not differ between alternatives. In comparing costs and consequences of alternative programmes, diere are 4 basic types of full economic evaluation: cost-minimization analysis, cost-effectiveness analysis, cost-benefit analysis and cost-utility analysis.
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Cost-minimization is a comparative approach to identify die least expensive provision from a set of alternatives widi die same outcome. Results are often reported in terms of cost per treated patient, aldiough diis is a measure of output radier dian outcome. Often, delicate and subjective judgement is necessary to discriminate cost analyses from cost-minimization. Therefore, we decided to exclude this type of analysis from our review. Cost-effectiveness analysis (CEA) is a method in which costs and consequences of some provisions are compared with dieir best alternatives. Costs are valued in money, while effects are measured in some natural unity. The unit of effect depends on the programmes that are being compared and may take the form of a cost per life saved or per saved life year or levels of function or proportion of patients in whom symptoms are controlled. Since die ultimate aim of healdi care programmes is to prevent morbidity and mortality, years of life gained are typically used as die unit of effect. ' In cost-benefit analysis (CBA), all costs and benefits, including die gains in healdi, are valued in monetary terms and the results are usually reported as a net cost or benefit. Although some audiors argue diat CBA can also be applied to one single strategy, we rule that out as it is not a full economic evaluation according to Drummond et al.'s definition. 10 Cost-utility analysis (CUA) can be seen as an extension of cost-effectiveness analysis in die sense drat changes in the quality of life are taken into account. The result of a CUA is usually a cost per quality adjusted life year (QALY) gained. QALYs combine quantity and quality of life into one single index which allows comparisons across programmes. Although diis type of analysis has the advantage of combining effects diat programmes can have on different outcomes by valuing the change in each outcome, die analyst is faced with, many problems, such as weighing different dimensions into one index 1 and valuing human life and suffering. 11 The result is an ongoing debate 12 and die development of alternative measures for CUA, for instance 'healthy years equivalent'. 1^'1 '* As die measurement of diese concepts have been pursued in very different ways, it seems too early to recommend standardization.
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Methodology of full economic evaluation: a check list
Because full economic evaluation is a radier extensive form of research, a check list is helpful. We used die check list of Drummond et al., containing 10 questions to be considered when assessing die appropriateness of die mediodology employed in a study (table 3) .
10 '
15
The first question, concerning die alternatives being compared and die viewpoint(s) underlying die comparison, is very general and relevant to all scientific efforts.
10
A comprehensive description of die competing alternatives (question 2) and substantiated evidence of die effectiveness of diese options (question 3) enables die reader to judge die usefulness, applicability and comparability of die programmes and to assess die completeness of die study. Sometimes, analysts eidier explicidy or implicitly choose the current programme as an alternative ('doing nodiing') to die new strategy, but we feel that diis choice should be substantiated in detail. The perspective of die study has to be clearly idendfied because of the consequences for die selection of relevant costs and outcomes (question 4). Most authors recommend die societal perspective in which all direct and indirect costs, widiin and outside die healdi care sector, are included. 1 • Sometimes, a narrower perspective can be adopted, for instance, die viewpoint of a diird-party payer, a care provider or the consumer. Each of diese alternatives is more limited dian die societal perspective and die consequent resource allocations may be suboptimal from the societal point of view. However, this is the very nature of decentralized decision making. All relevant costs and outcomes of all relevant alternatives have to be included in the analysis (question 5) and valued sensibly (question 6). This often raises problems, because the real costs are sometimes unknown. Economists are reluctant to use tariffs or charges in economic evaluation, because these are negotiated over between healdi care providers and third-party payers and usually do not represent real costs. In practice it can be very difficult and costly to reveal the actual costs, so we adopt a pragmatic approach in this matter. The stream of costs and outcomes have to be discounted over time (question 7), because different programmes generally have different time profiles of costs and/or consequences, but must be compared at one point in time (usually the present). In this way we eliminate the consequences of time preference, i.e. the phenomenon that individuals and society prefer money or resources now instead of later because of the benefits in the interim, even in a world without inflation and bank rates. 10 The social rate of time preference is a measure of society's willingness to forgo consumption (gratification) today in order to have a greater consumption (gratification) tomorrow. Although there remains some debate, die most commonly used rate at present is 5% per year. 15 In the early 1980s, this choice lacked serious empirical backing, but a study of short-and long-term interest rates in 9 countries came up with supportive evidence to fix the discount rate at 5%. 18 Another point of discussion concerns the discounting of heakh effects, 19 for which some authors advocate lower interest rates, 20 but there seems to be no solid ground to justify a specific regimen of time preference.
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Another important foundation of economic evaluation is the concept of marginal analysis (question 8). In order to make the proper allocation decisions for scarce resources, it is necessary to examine additional or marginal effects of additional or marginal increases in resource expenditure. Table 3 A check list for assessing economic evaluations in health care
1 Was a well-defined question posed in an answerable form?
2 Was a comprehensive description of the competing alternatives given?
3 Was there evidence that the programme's effectiveness had been established? How strong was the evidence (through a randomized, contolled clinical trial)?
4 Were all important and relevant costs and consequences for each alternative identified?
5 Were costs and consequences measured accurately in appropriate physical units?
6 Were costs and consequences valued credibly?
7 Were costs and consequences adjusted for differential timing?
8 Was an incremental analysis of die costs and consequences of alternatives performed?
9 Was a sensitivity analysis performed?
10 Did presentation and discussion include all of the issues that are of concern to users?
Source: reference 15
Sensitivity analysis should also show the influence of various discount rates on die results of the study (question 9). In general, sensitivity analysis is used to assess die robustness of die assumptions underlying the study and of die qualitative conclusions and to identify areas for further research on diose variables which are crucial to die results. The last question of die check list is crystal clear, but quite often researchers 'forget' to address, for instance, die distributional, legal and ediical issues relevant to die (introduction of die) programme. Finally, die analyst should be as explicit as possible about the various methodological, technical and value judgements he or she has made carrying out die study.
REVIEW OF THE LITERATURE Selection methods
We used MEDLINE (1984 MEDLINE ( -1993 on CD-ROM to find publications on die 3 chronic diseases. Search procedures in CD-ROM make use of die medical subject headings of die Index Medicus, which are based on bodi die title and die contents of a publication. We selected all references, including full economic evaluations, on diabetes mellitus (widi 8 medical subject headings: diabetes mellitus, ketoacidosis, angiopadiies, coma, diet, nephropadiies, neuropadiies and retinopadiy), rheumatoid arthritis (widi 3 headings: arthritis-rheumatoid, osteoardiritis and osteomyelitis) and chronic obstructive pulmonary diseases, including asdima (widi 'lung-disease-obstructive' as the heading). This sample of publications was completed, using die Economic Evaluation Bibliography of approximately 1,900 publications, ranging from journal articles and editorials to discussion and research papers. 21 According to die audiors, this bibliography covers almost 100% of die English language references over die period . For OOPD and asdima, diis article is also based on a recent review. 22 Drummond et al.'s definition 10 was used to classify an economic study as a full economic evaluation. Finally, to judge die rigour of an economic evaluation, we used die check list, as explained above. Table 4 presents the stream of publications for die 3 chronic diseases during die period 1984-1993. The average number of publications varies from 2,100 to 2,780 papers per year, of which 0.3% fits die Index Medicus' subject heading 'economies'. Although diis heading is broad, it provides us widi adequate access to die full economic evaluation literature. The bibliography contains 1,887 publications of which 56% are not on full economic evaluations: 18% have been classified as cost analysis studies (including cost of illness studies), 21% as review articles and methodological papers and 17% as other papers, including comments and letters to the editor(s). For all diseases togedier, CEA is the most commonly used method (31%), followed by CBA (10%) and CUA (3%). The latter is a new but rapidly growing area of work, although the quality of technical execution is still poor and die concept of utility itself is debated upon, as mentioned above. 15 ' 23 One-fifth of all economic studies are concerned with diseases of the circulatory system and 13% focused on infectious and parasitic diseases. Mental disorders have been studied in 5% of all publications. The bulk, however, is classified into the category of odiers, also including the 3 chronic diseases central to this paper. The most important type of interventions described are drugs (22%), therapy (26%) and prevention (17%). Alternatives in health service organization or location of care have been studied less frequently (13%).
General results
21
These general figures raise the suspicion that chronic care is lacking attention from economists. Table 5 further demonstrates this caveat. In total, the references to die 3 chronic diseases cover only 5% of all economic literature. Relatively more attention has been paid to cost(-minimization) analysis, particularly cost of illness studies, but we did not classify these as full economic studies. Full economic evaluation studies into chronic diseases and the elderly have been performed as often as in other health care fields, accounting for approximately 45% of all references in the economic literature. Other economic, especially cost of illness, studies may serve to clarify the economic significance of disease-specific intervention. If any publication has been used in diat way, it will be stated clearly. (13) 1,864 (9) 1,545 (20) 
Total number 26,274 (64) 23,028 (65) 27,824 (67) Source: Medline (70) 191 (23) 56 (7) 827 (100) Methodological rigour
The last line of table 5 shows that die completeness of die bibliography is (almost) perfect for rheumatoid arthritis and diabetes mellitus, but far less satisfying for COPD and asdima. Our review research resulted in 8 more studies than found by Backhouse et al. 21 We used die same sources, so to us die reason remains unclear, odier dian our special interest in this topic. Some references (author names) in die bibliography were spelt incorrectly. Table 6 summarizes our efforts to address the mediodological rigourness of die full economic evaluations. In each field of chronic diseases a small number of articles could not be assessed in diis way, because diey have been published as abstracts only. The methodological quality varies gready, although in most cases diere is a good research question and evidence of die effectiveness of a particular programme. The relevant alternatives and die identification of all costs and outcomes are not always spelt out in much detail. Greater caveats are observed widi respect to discounting, incremental analysis (diough this is irrelevant when a study is based on a randomized trial) and sensitivity analysis. The accuracy by which costs have been measured and valued is often unclear and not explained in sufficient detail. Overall, studies into die 3 diseases do not differ from each odier when assessed against Drummond et al.'s check list.
•
THE ECONOMIC LITERATURE ON SELECTED CHRONIC DISEASES
Diabetes meUitus
The estimates for the prevalence of diabetes mellitus (DM) vary from 1 to 2%, 24 ' 25 but approximately 50% of die non-insulin-dependent diabetes mellitus (NIDDM) remains undiagnosed. 26>27 The most common complications associated widi DM are impaired vision, cardiovas- 28 Nevertheless, most studies focused on the direct costs only, with a few studies on the cost of illness aspects of DM.
29 " 51 The health cost of diabetes is estimated to account for 4-5% of all health care expenditures. Other social i.e. indirect costs, due to lost production and premature death, account for 40-50% of total cost of illness.
29
Until now, there have been a few intervention studies focusing on the effectiveness of dier or medication." Table 7 shows that most economic appraisal has been dedicated to screening, 42 originated from the same research group, all using the same populationbased simulation model. Screening and treatment of diabetic retinopathy received a good deal of attention, accounting for 60% of all references and has been proven to be cost-effective from a societal and governmental perspective. From the viewpoint of a third-party payer, however, some additional incentives might be necessary. Screening for the early detection of diabetic retinopathy is a very cost-effective strategy, even if only 60% of the insulin-dependent patients are being covered. Each person receiving comprehensive eye examinations and appropriate treatment at the earliest signs of disease represents a savings of nearly 10.000 USS.
40 '
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For cases of retinopathy detected early, laser surgery can prevent further damage to the eye, with a success rate of nearly 90%. Unfortunately, it is not easy to detect diabetic retinopathy, because no noticeable loss of vision appears until the damage is well advanced. In The Netherlands, a recent full economic evaluation of ophthalmic care, including ophthalmoscopy and photocoagulation, demonstrated clear net benefits of screening for IDDM patients but failed to provide sufficient (economic) arguments to justify special ophthalmic care for N1DDM patients. But these findings depend on the assumptions about the age of onset of diabetic retinopathy and the actual moment of diagnosing this event: the younger the age of onset, the more favourable the cost-effectiveness ratios. Screening for NIDDM did prove to be cost-effective, although less so than for IDDM because the threat of blindness is less severe. Annual eye examinations using dilation of the pupils has proven to be the most effective screening strategy, both in the USA 39 and in Sweden, 40 even for relatively low rates of compliance. Health education programmes have been studied more frequently than suggested by table 6, accounting for almost 20% of all references in the economic literature, but full economic evaluation studies have been reported only 3 times.
Less popular are diet and nutrition (although good for the single cost-utility study, focusing on a diet plus exercise programme for NIDDM), 46 and out-patient activities. 47 Antibiotics against osteomyelitis, which is part of the natural progression of diabetes in the lower extremities, is not effective, but early amputation of the toe in combination with antibiotics has proven to be cost-effective. 49 In general, many behavioural and education programmes for diabetes seem to be cost-beneficial, ^although there is little really strong evidence and some questions remain Three studies focused on medication, 2 for patients with rheumatoid arthritis 58159 and 1 for patients widi osteoarthritis. 60 Thompson et al. 58 evaluated the cost-effectiveness of auranofin (an oral gold preparation) in a randomized trial of RA patients with a placebo control group and found significant, albeit slight, improvements in 4 out of 6 clinical outcome parameters and 1 negative side-effect (diarrhoea). However, medical costs (including paid help) and indirect costs (travelling time of patients and work disability) were higher for the experimental group. Kvien et al. 60 concluded that a variable dosing regimen of naproxen for patients with knee and hip arthritis is superior to a fixed regimen, resulting in a lower drug consumption (by 20-30%), similar levels of efficacy and possibly better tolerance.
Two other studies focused on different surgical strategies for total joint arthroplasty 61 and advanced degenerative knee arthritis. 62 In the latter study, which used a model simulating 25 years of experience from primary surgery at age 40 years and included a sensitivity analysis, total knee arthroplasty dominated 3 other surgical strategies, such as unicompartmental resurfing and tibial osteotomy. Although total joint arthroplasty in itself is radier expensive, other direct costs of medical and long-term care are much lower. 61 " 64 However, further evidence based on randomized trials with different strategies is necessary. The sixth study is a very early full economic evaluation (1969), addressing a wide range of RA treatments at a rheumatic centre (a 48 bed hospital) in Glasgow. The present value of benefits exceeded total costs under all assumptions explored in the sensitivity analysis, but the treatment at the centre was not compared to any other alternative (implicitly 'doing nothing'). The last 2 studies compared 2 different locations of care for patients with rheumatoid arthritis, i.e. in-patient care with intensive out-patient therapy. 66 ' 67 In the latter study, hospitalization improved by a factor of 3 but costs were a factor of 2.5 higher. Thus, although this study found slightly better outcomes at substantially higher costs, society might be reluctant to invest in the new alternative, because of concern for the national healtli care budget, although such a strategy would clearly improve the quality of life of patients. 54 ' 58 ' 61 Other researchers, although not undertaking a full economic evaluation, did not find any possibilities of achieving significant reductions of hospitalization rates for RA patients. 68 -69 Table 8 Economic appraisal of rheumatoid arthritis: main characteristics of the studies, by intervention (n-8) The results from this pan of the review are not promising, but are slightly misleading as long as they do not take into account the non-economic aspects of chronic diseases, such as the quality of life of RA patients, who are willing to pay quite a large part of their income for treatment of their disease. 70 Chronic obstructive pulmonary diseases and asthma COPD is generally used as a broad term for chronic bronchitis, emphysema, and chronic air-flow limitation. In English language literature, asthma is distinguished from COPD, following international consensus. In The Netherlands, the combined prevalence rates of the 2 conditions (encompassed in the acronym Cara) vary from 10-20% for men (especially elderly men suffer from COPD) and 5-10% for women or children who especially suffer from asthma (table I) . Approximately 4% of all health care costs are caused by COPD and asthma. The associated burden of illness is considerable and will increase further because of ageing. 71 Continuous search during recent years resulted in 20 full economic studies published over the years [1980] [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] [1991] Toevs 1985 Toevs 1990 Toevs 1987 Toevs 1983 Toevs 1987 Toevs 1991 Toevs 1991 Toevs 1991 Toevs 1988 Toevs 1983 Toevs 1984 [73]
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[92] Dutch multicentre randomized intervention trial in asthma and COPD has proven that long-term therapeutic intervention directed at reducing bronchoconstriction and airways hyper-responsiveness, adding corticosteroids to a regimen of beta-2-agonists, is more cost-effective than treatment with a beta-2-agonist plus an anticholinergic drug; the latter in turn is superior to therapy with a single bronchodilating agent.
90 -94 ' 95 The same favourable results hold for children.
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Rehabilitation programmes have been subject to CBA 97 and CUA. 98 The latter is the only CUA we found in the economic literature on COPD and asthma. This is remarkable, because the quality of life as an outcome measure of interventions is equally or even more important than quantity of life or other outcome measures. 99 ' 100 Behavioural programmes to improve compliance to exercise and rehabilitation have proven to be effective.
9^ '98 However, the samples used in these studies ( Our review shows that in chronic diseases full economic evaluation, which we used here in the strict definition, i.e. excluding cost (-minimization) analysis, is scarce. We were able to locate 20 publications on COPD/asthma, 15 on diabetes mellitus and 8 on rheumatoid arthritis. These studies account for 0.2% of all publications concerning these diseases during the period 1984-1993. In chronic diseases, economists generally used CEA (in more than 70% of the studies), followed by CBA (20%) and CUA (9%). In rheumatoid arthritis CUA has been done slightly more often (25%). These conclusions confirm the findings in the economic bibliography. Our review has revealed some caveats in the methodology of full economic studies of programmes targeted at COPD/asthma, RA and DM. Full economic evaluation in COPD/asthma, RA and DM has revealed many effective interventions in chronic diseases. Some programmes for early discharge from hospitals are cost-effective for certain groups of RA patients, although the results in different locations of care are not decisive and less favourable when the total costs of home care and informal care are fully included. The same holds for home care (as an alternative to institutional care) for DM and COPD/asthma. In highly selected patient populations, home care seems to be cost-effective but effect measures are frequently hampered by small samples and intervening factors. Pharmacotherapy did not get much attention, aldiough it is often an important therapeutic intervention, especially in COPD/asthma. All the studies we found came up widi favourable results. The small number of studies is probably due to the fact that it is unethical to withhold effective medication from control groups; 'doing nothing' is not a realistic alternative. Screening and treatment of diabetic retinopathy received a good deal of attention, accounting for 60% of all DM references and has been proven to be very cost-effective, especially for IDDM and even for less favourable coverage and compliance rates. Behavioural and education programmes, which are of special interest to patients with asthma or DM, seem to be cost-beneficial, although the long-term effects and the possibilities of generalizing results to the population remain questionable. This review makes it clear that the selection of patients is very important for the cost-effectiveness profile, but still remains difficult.
There are many problems and challenges to applying economic appraisal to chronic diseases. It is difficult to acquire precise cost data in relation to individuals consuming medical and social services, in and outside institutions, comparing the real costs of alternatives for specific groups of individuals. Secondly, one has to make arbitrary decisions to split so-called joint costs when comparing different service patterns for a group of individuals. Other problems are related to co-morbidity, heterogenity in need and demand for care, effects of supply-induced demand by offering new forms of care, the problem of preference drift (as shown here for COPD) and consequent conceptual problems with the meaning and measurement of quality of life. Costs and financing should be clearly distinguished; governmental agencies tend to focus on the latter, thus limiting the perspective of the study and 'forgetting' that the financial burden of long-term home care programmes shifts from public to private funding with consequent cumulative effects for chronic and elderly patients, who are already in the lower social classes. The problem of measurement and valuation of informal care has rarely been tackled effectively until now, but is very important in chronic and long-term care 730
In the care sector, objective measurement of outcome is much more difficult than in the cure sector and sometimes even impossible. Problematic to the economic evaluation of alternative location of care strategies is that home care is a basket of very different activities of different professionals, resulting in many identification problems (which intervention causes which effect?). Services in the chronic care sector are meant to serve many objectives, which go beyond the single dimension of health status. These objectives have to be made explicit in order to develop indicators to fully assess the outputs of an intervention. Standardized generic quality of life instruments are needed to allow comparisons between various interventions, ^ but additional disease-specific measures and questionnaires are necessary 1 "' and will also increase the sensitivity to change.'*'' Intermediary outcome measures, like, for instance, referral patterns or length of stay, may say something about the process of care, but often do not provide sufficient information for an economic appraisal. Most relevant is probably the subjective measurement of outcome, asking chronic patients to assess the outcomes of services. More fundamentally, there is a need to use an integrated utility concept. Health status, pain, comfort, safety and independence are relevant dimensions of a broad concept of well-being in the chronically ill, as has been illustrated for rheumatoid arthritis. 58 ' 61 ' 10 'The concepts underlying the chronic care go far beyond the statement of Gerard and Mooney diat "only health gain is being sought from health care resources". 103 The challenge remains to operationalize these concepts and make them applicable to economic evaluation of health care programmes for the chronically ill.
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